Literature DB >> 7718018

The effects of fibrates on lipoprotein and hemostatic coronary risk factors.

G Schonfeld1.   

Abstract

The effects of fibrates on lipoprotein profiles and lipoprotein physiology, as well as on selected coagulation and fibrinolytic factors are reviewed. It is concluded that the action of fibrates on these systems is such as to render the fibrates beneficial in atherosclerosis prevention.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7718018     DOI： 10.1016/0021-9150(94)90090-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


  11 in total

1.  PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.

Authors:  K Schoonjans; J Peinado-Onsurbe; A M Lefebvre; R A Heyman; M Briggs; S Deeb; B Staels; J Auwerx
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

2.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.

Authors:  Tineke Kok; Vincent W Bloks; Henk Wolters; Rick Havinga; Peter L M Jansen; Bart Staels; Folkert Kuipers
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

3.  Inhibitory effects of fenofibrate on plasminogen activator inhibitor-1 expression in human endothelial cells.

Authors:  Chunxia Dong; Yu Hu; Huafang Wang; Chunyan Sun; Yadan Wang; Wenjuan He; Xiaoping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  Bela F Asztalos; Dorothea Collins; Katalin V Horvath; Hanna E Bloomfield; Sander J Robins; Ernst J Schaefer
Journal:  Metabolism       Date:  2008-01       Impact factor: 8.694

6.  Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.

Authors:  Min-Jeong Shin; Alka M Kanaya; Ronald M Krauss
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

Review 7.  Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

Authors:  C M Spencer; L B Barradell
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

8.  Association of PPARα Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study.

Authors:  Sreeja Purushothaman; V K Ajitkumar; R Renuka Nair
Journal:  ISRN Cardiol       Date:  2011-04-07

Review 9.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

Review 10.  Update on the use of fibrates: focus on bezafibrate.

Authors:  Ilan Goldenberg; Michal Benderly; Uri Goldbourt
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.